
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Photoclinic section editor CFP
Dr Kamat Professor of Pediatrics at Wayne State University in Detroit. He is also Director of the Institute of Medical Education and Vice Chair of Education at Children's Hospital of Michigan, both in Detroit.
Photoclinic Submission Guidelines.






